Transmigration of PBMNCs from beta-IFN-1b-treated MS patients: a one-year longitudinal study.
To evaluate the effects of in vivo beta-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during beta-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.
Gelati
M
M
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
Corsini
E
E
Dufour
A
A
Zaffaroni
M
M
Milanese
C
C
La Mantia
L
L
Massa
G
G
Salmaggi
A
A
D000328:Adult; D002465:Cell Movement; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000166:cytology*; D008137:Longitudinal Studies; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*
D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a